![Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
23 September 2020
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...